trial

Treatment of Auditory Hallucinations in Schizophrenia With Bilateral Theta Burst Stimulation

NCTId NCT02670291
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 138 (actual)
Sponsored by University Hospital Tuebingen
Primary completion 2023-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
138 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2017-01
Primary completion
2023-11
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
MagPro Cool-B65A/P, Magventure

Sponsors

University Hospital TuebingenLead Sponsor
German Research FoundationCollaborator
Institute for Clinical Epidemiology and Applied Biometry, University Tuebingen, GermanyCollaborator
Center for Clinical Studies, University Tuebingen (ZKS), GermanyCollaborator
Ludwig-Maximilians - University of MunichCollaborator
University of UlmCollaborator
Heidelberg UniversityCollaborator
Department of Psychiatry and Psychotherapy; Unversity Augsburg, GermanyCollaborator
Department of Psychiatry and Psychotherapy, LVR Duesseldorf, GermanyCollaborator

Investigators

1
Christian Plewnia, Prof., MDPrincipal Investigator

Sites

1 total
Tübingen, Germany

Facts & assertions

4 sourced
Enrollment
138
Phase
NA
Primary Completion Date
2023-11
Status
COMPLETED
relationships
The graph out of here
drug
MagPro Cool-B65A/P, Magventure
drug
lead_sponsor
University Hospital Tuebingen
company
collaborator
German Research Foundation
company
Institute for Clinical Epidemiology and Applied Biometry, University Tuebingen, Germany
company
indication
Schizophrenia
indication
Hallucinations
indication
Auditory Hallucinations
indication
investigator
Christian Plewnia, Prof., MD
person